Ticker	Current Price	Change	Graph
IBB	109.79	1.14 (1.05%)
XBI	82.40	0.49 (0.6%)

Deals, Devices, Tech

With J&J deal to assess value of Apple watch in atrial fibrillation, tech giant fortifies its foray into healthcare

Deals

Looking to make a splash at JPMorgan, Eli Lilly rushed to put its $8B buyout deal together for Loxo in 10 days

Bioregnum, Business

Short seller Citron draws fresh blood going after another biotech scalp — but can it still cut that deep?

Latest

Novartis teams up with Oxford researchers to crunch big data into clinical insights →

Scoop: Forma axes discovery biology team as part of a broader reorganization →

NIH researchers report animal model validation for stem cell-based approach to advanced dry AMD →

UPDATED: Zafgen has something to cheer as diabetes drug makes the cut in PhII study →

Alzheon hits another dead end funding its Alzheimer's program, pulls second IPO attempt →

Second time's a charm for osteoporosis drug from Amgen, UCB as FDA panel grants its blessing →

FDA revises draft guidance on rare disease drug R&D →

Dragonfly preps clinical takeoff, inking a collaboration pact with MD Anderson →

UPDATED: Aptinyx shares crater as lead drug fails in PhII neuropathic pain study →

Top News

Blocking PD-L1 production in mice, UCSF team spotlights preclinical promise of a Pfizer-backed I/O drug

Amber Tong

Live to 150? Jim Mellon and the crew at Juvenescence just raised $46M more to give it a try

John Carroll

Five Prime cuts 41 jobs, days before presenting data at ASCO meeting of GI cancers

Natalie Grover

Gottlieb, Marks detail plans to advance development of cell and gene therapies

Michael Mezher

Two more big pharma vets at Roche, AstraZeneca make the leap to top biotech R&D jobs as the great migration continues

John Carroll

More news

Protocols

Quick hits from around the biopharma web

Jan 17

Bayer axing 665 workers at US campus; NASH biotech pumps up share price with an ‘interim’ snapshot

Jan 16

AstraZeneca signs deal to promote product made in China — in mainland China; Israeli deep brain stimulation co Brainsway sets stage for $30M Nasdaq IPO

Jan 15

Seres promotes CFO Eric Shaff to succeed Pomerantz as CEO; Exelixis' Cabometyx bags US approval for liver cancer

Jan 14

FDA offers Pfizer priority review for tafamidis; Clarivate to merge with Churchill Capital

More Protocols

Peer Review

Weekly biopharma careers news report

Jan 14

CMO Sean Bohen joins exodus at AstraZeneca during a major R&D leadership overhaul

Jan 11

Ironwood recruits CMO on the eve of split-up; Roche vet Margrit Schwarz joins Genevant

Jan 10

Roche exec Pearl Huang rejoins biotech as CEO of Cygnal — Flagship's bet on 'exoneural biology'

Jan 5

How much does it cost to hire a top Big Pharma exec to run a biotech? Here are 4 (very) fresh examples

More peer review

Premium

So what did we learn from JPMorgan week? Buckle up, it’s going to be a bumpy ride

‘It’s us against the world’: And George Yancopoulos wants you to know they are beating the world — big time

The 2018 breakdown on a chart-topping set of new drug approvals — and the 5 big things we learned from it

Winners and losers at #ESMO18

Exclusive: At Hal Barron’s R&D group at GSK, consensus is out, leaders are in and watch out for an ‘intense drive’ to spur the late-stage pipeline

With its rep on the line, Celgene's newly-filed safety study spurs fresh worries over fate of ozanimod

Bioregnum

The view from John Carroll

Jan 17

Short seller Citron draws fresh blood going after another biotech scalp — but can it still cut that deep?

Jan 16

Allergan and its Mohawk allies pitch their sovereign immunity case to SCOTUS. And the timing couldn't be worse

Jan 11

So what did we learn from JPMorgan week? Buckle up, it’s going to be a bumpy ride

Jan 2

New Year’s Day price hikes on blockbuster drugs set the stage for a big debate

More opinion

Marco

Hot BioTwitter bot - last updated ago

Most Viral

Immunomedics Receives Complete Response Letter From FDA for Sacituzumab Govitecan Biologics License Application

GlobeNewswire News Room Immunomedics, Inc. a day

FDA rejects Immunomedics breast cancer drug, extending long drought - STAT

STAT a day

New York Confronts Its Worst Measles Outbreak in Decades

New York Times a day

Xconomy: FDA's Gottlieb Adds Confusion to Aimmune's Claims of Shutdown Delay

Xconomy Alex Lash a day

ASCO GI19 Highlights | Biotech Strategy Blog

Biotech Strategy Blog a day

Lipocine reckons seven of nine is good enough to disclose

Evaluate.com a day

Did neurons arise from an early secretory cell?

Science | AAAS a day

Apple Has Just Ushered In The Era Of Digital Health

Forbes a day

How Vertex hopes to reach more patients with Arbor's CRISPR tools

BioCentury a day

The health care innovation bubble

ScienceDirect a day

Latest

Science | AAAS

Did neurons arise from an early secretory cell?

NBC News

DNA test company 23andMe now fueling medical research

Washington Post

FDA directs dwindling resources toward reviewing new drugs

GlobeNewswire News Room

Immunomedics Receives Complete Response Letter From FDA for Sacituzumab Govitecan Biologics License Application

STAT

FDA rejects Immunomedics breast cancer drug, extending long drought - STAT

BioCentury

How Vertex hopes to reach more patients with Arbor's CRISPR tools

Xconomy

Xconomy: FDA's Gottlieb Adds Confusion to Aimmune's Claims of Shutdown Delay

New York Times

New York Confronts Its Worst Measles Outbreak in Decades

Forbes

Apple Has Just Ushered In The Era Of Digital Health

Biotech Strategy Blog

ASCO GI19 Highlights | Biotech Strategy Blog

Hot This Week

1

GlobeNewswire News Room

Immunomedics Receives Complete Response Letter From FDA for Sacituzumab Govitecan Biologics License Application

2

LifeSciVC

The Game Isn’t Worth The Candle: Reflections On The JPM Healthcare Conference

3

ENDPOINTS NEWS

Gottlieb, Marks detail plans to advance development of cell and gene therapies

4

Pink Sheet

US FDA's Biosimilars Chief Leah Christl Plans Departure

5

STAT

A longer shutdown at FDA could put anticipated new drugs in jeopardy

6

STAT

FDA rejects Immunomedics breast cancer drug, extending long drought - STAT

7

ENDPOINTS NEWS

May the candle burn forever: Polite reminders about the JPMorgan confab

8

New York Times

New York Confronts Its Worst Measles Outbreak in Decades

9

STAT

New details revealed about Purdue's marketing of OxyContin- STAT

10

STAT

With J&J deal to assess value of Apple watch in atrial fibrillation, tech giant fortifies its foray into healthcare

Looking to make a splash at JPMorgan, Eli Lilly rushed to put its $8B buyout deal together for Loxo in 10 days

Short seller Citron draws fresh blood going after another biotech scalp — but can it still cut that deep?

Latest

Novartis teams up with Oxford researchers to crunch big data into clinical insights →

Scoop: Forma axes discovery biology team as part of a broader reorganization →

NIH researchers report animal model validation for stem cell-based approach to advanced dry AMD →

UPDATED: Zafgen has something to cheer as diabetes drug makes the cut in PhII study →

Alzheon hits another dead end funding its Alzheimer's program, pulls second IPO attempt →

Second time's a charm for osteoporosis drug from Amgen, UCB as FDA panel grants its blessing →

FDA revises draft guidance on rare disease drug R&D →

Dragonfly preps clinical takeoff, inking a collaboration pact with MD Anderson →

UPDATED: Aptinyx shares crater as lead drug fails in PhII neuropathic pain study →

Top News

Protocols

Peer Review

Premium

So what did we learn from JPMorgan week? Buckle up, it’s going to be a bumpy ride

‘It’s us against the world’: And George Yancopoulos wants you to know they are beating the world — big time

The 2018 breakdown on a chart-topping set of new drug approvals — and the 5 big things we learned from it

Winners and losers at #ESMO18

Exclusive: At Hal Barron’s R&D group at GSK, consensus is out, leaders are in and watch out for an ‘intense drive’ to spur the late-stage pipeline

With its rep on the line, Celgene's newly-filed safety study spurs fresh worries over fate of ozanimod

Bioregnum

Most Viral

Latest

Hot This Week

Contact Endpoints News

Sign in to Endpoints News

Request a magic link

Set a new password